Mereo BioPharma Group plc Revenue Disclosure
13. Revenue and Cost of revenue
ReproNovo Partnership
In December 2023, the Company and ReproNovo SA. (“ReproNovo”) entered into a global licensing agreement for the development and commercialization of leflutrozole (the “ReproNovo Licensing Agreement”). Under the terms of the ReproNovo Licensing Agreement, ReproNovo received an exclusive worldwide license and will be responsible for all future research, development and commercialization of leflutrozole. Additionally, the Company received an upfront payment of $1.0 million and will be eligible to receive up to $64.3 million in total in development, regulatory and commercial milestones and tiered royalties ranging from the low-to-mid-single digits on global annual net sales of leflutrozole.
A single performance obligation was identified in this agreement which is the promise to grant the license to develop and commercialize leflutrozole.
The Company recognized a milestone payment of $0.5 million as revenue under the terms of the ReproNovo Licensing Agreement during the year ended December 31, 2025 following confirmation by ReproNovo that the first participant had been included in a Phase 2 trial of leflutrozole. No revenue was recognized during the year ended December 31, 2024.
As a consequence of the milestone payment received, and in accordance with the terms of the 2015 asset purchase agreement with Novartis, the Company recognized $0.1 million as cost of revenue during the year ended December 31, 2025. No cost of revenue was recognized during the year ended December 31, 2024.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 19, 2026 | Showing above |
| 2024 | Mar 26, 2025 | |
| 2023 | Mar 27, 2024 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.